Gabapen tablets 200 mg for epilepsy (Gabapentin, Neurontin)

General information on Japanese Gabapen tablets 200 mg for epilepsy (Gabapentin, Neurontin)

Package details: 100 tablets

Manufacturer: Fuji Pharmaceutical Co. Ltd., Japan

Active ingredients: gabapentin (chemical formula C9H17NO2)

Medical effect: Gabapen tablets are effective for the treatment of partial seizures of epilepsy with concomitant therapy.

Contraindications and precautions: do not use for pregnant or breastfeeding women. Do not use for patients with renal dysfunction.

Patient should consult with their doctor in case of any signs of overweight, as this medicine may cause the increase of the body weight.

If an allergic reaction occurs, stop taking the medicine and consult with your doctor. If you’re taking any other medication or receiving any other treatment, you have to consult with your doctor before use.

As this medicine may cause lack of concentration or reflex action, patient should avoid working at height or operating dangerous machines, such as driving a car.

Dosage and administration

• For adults: start with taking 1 Gabapen tablet (200 mg of the active ingredient) 3 times on the first day. On the second day, take 2 tablets (400 mg) 3 times. From the third day on, take 2-3 tablets (400-600 mg) 3 times a day as a maintenance dose. For adults with renal disorder, the dosage and dose frequency may be adjusted. The doctor in charge may adjust the dosage according to the symptoms but the maximum daily dose of 12 tablets (2,400 mg) should not be exceeded.
• For children over 13 years old: start with taking 1 tablet (200 mg of the active ingredient) 3 times on the first day. On the second day, take 2 tablets (400 mg) 3 times. From the third day on, take 2-3 tablets (400-600 mg) 3 times a day as a maintenance dose. The doctor in charge may adjust the dosage according to the symptoms but the maximum daily dose of 12 tablets (2,400 mg) should not be exceeded.
• For children 5 to 12 years old: take 10 mg per 1 kilogram of the body weight, dividing this amount into 3 doses on the first day. On the second day, take 20 mg/kg in 3 divided doses. From the third day on, take 25-35 mg/kg in 3 divided doses as a maintenance dose. The doctor in charge may adjust the dosage according to the symptoms but the maximum daily dose of 50 mg/kg should not be exceeded. The dose also should not exceed the dose in adults and children over 13 years old.
• For children 3 to 4 years old: take 10 mg per 1 kilogram of the body weight, dividing this amount into 3 doses on the first day. On the second day, take 20 mg/kg in 3 divided doses. From the third day on, take 40 mg/kg in 3 divided doses as a maintenance dose. The doctor in charge may adjust the dosage according to the symptoms but the maximum daily dose of 50 mg/kg should not be exceeded. The dose also should not exceed the dose in adults and children over 13 years old.

Please note that this preparation contains 200 mg of the active ingredient in a tablet. It may be combined with other antiseizure drugs.

The maximum time interval between doses should not exceed 12 hours.

How effective are Gabapen tablets 200 mg from Japan for epilepsy (Gabapentin, Neurontin)?

Gabapen tablets contain gabapentin, a derivative of gamma-aminobutyric acid (GABA). It works by decreasing calcium inflow and free neurotransmitter in the excitatory presynaptic terminal and increasing GABA amount in the brain to maintain and strengthen the GABA in nerve function. Gabapentin can cross the blood–brain barrier and enter the central nervous system significantly better than GABA itself.

Who should use Gabapen tablets 200 mg from Japan?

Gabapen tablets are used for the treatment of partial seizures of epilepsy with concomitant therapy. Studies including more than 2000 patients showed that gabapentin is safe, well-tolerated and effective, decreasing seizure frequency for at least 50% in 76% of patients and making absolutely seizure-free 46.4% of patients (M. J. Morrell, M. J. McLean et al. “Efficacy of gabapentin as adjunctive therapy in a large, multicenter study”. Seizure, 2000, 9(4): 241-8).